Advance your students’ periodontal education and experience
Will your students be prepared for the challenges that await them? How will they deal with the 1 out of 2 adult Americans who suffers from periodontal disease?1
The ARESTIN® Student Access Program is designed to provide students with an understanding of the risks and benefits of a comprehensive treatment plan as well as hands-on clinical training, that includes:
- Scaling and root planing (SRP)
- ARESTIN® (minocycline HCl) Microspheres, 1 mg
Once your students have completed the program, they will have the knowledge to succeed when faced with the challenges of helping patients to take control of their periodontal disease.
Note: Returning instructors are required to re-enroll in the program each school year.
Once you are registered for the ARESTIN® Student Access Program, you should expect to receive
- 2 PowerPoint lectures
ARESTIN® 101:
Introduction of ARESTIN® for the Treatment of Periodontal Disease
ARESTIN® 201:
Periodontal Case Development and Patient Selection - A complete program guide
- In-class, laboratory, and clinical student assignments
- Reading and evaluation materials
- ARESTIN® Student Trial Kits (1 per student; each 1 contains 12 ARESTIN® Cartridges for clinical use and the ARESTIN® Prescribing Information)
- And more
An overview of the ARESTIN® Student Access Program
The ARESTIN® Student Access Program is designed to complement your current periodontal curriculum. The ARESTIN® Student Access Program is divided into 2 sections.
ARESTIN® 101 is an introduction to periodontal disease and treatment with ARESTIN® + SRP. Clinician-patient communication is also highlighted in this section.
- Classwork focuses on disease state and clinical efficacy and safety data
- Laboratory session focuses on proper placement of ARESTIN® and communication techniques that can be used to explain periodontal disease and treatment options
In ARESTIN® 101 you can expect your students to learn:
- The risks and benefits of comprehensive periodontal treatment including ARESTIN® + SRP
- Important Safety Information
- How and when to use ARESTIN® appropriately
- The importance of good patient communication
ARESTIN® 201 deals with the clinical use and application of ARESTIN® with an emphasis on patient selection and case study development.
- Classwork focuses on appropriate patient selection and treatment planning
- Clinical session focuses on periodontal patient case development and treatment with ARESTIN®
In ARESTIN® 201 you can expect your students to learn how to:
- Prepare a treatment plan for a virtual periodontal patient
- Develop a periodontal case study using the ARESTIN® 201 Periodontal Case Study Content Guidelines
- Discuss the Periodontal Diagnostic Guidelines
- Demonstrate competency in placing ARESTIN® (minocycline HCl) Microspheres, 1 mg in the clinical setting
If you'd like to discuss the program further or have questions, please call or email Debbie Rosema, RDH, BS at: 1-888-553-6010 ext. 0627 or drosema@orapharma.com
ARESTIN® Student Access Program Materials
Faculty Education Folder, including a detailed program guide. These materials are also available to download at your convenience
Student Education Folders, including patient education materials (1 folder/student)
ARESTIN® Demonstration Packs (practice cartridges) for use on typodont (not included)
Student ARESTIN® Kits, including 12 ARESTIN® Cartridges for patient use
(1 kit/student)
Two ARESTIN® Handles (Additional handles may be purchased when you complete your School Enrollment Form)
ARESTIN® is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.
IMPORTANT SAFETY INFORMATION
ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.
Please see Full Prescribing Information
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
ARESTIN® and MyArestin.com® are registered trademarks of OraPharma, Inc.
This site is published by OraPharma, Inc. which is solely responsible for its contents. It is intended for visitors from the United States.
Please read the Prescribing Information
Manufactured for OraPharma, Inc. © OraPharma, Inc. 2009-2012 A-1080-11